Therapeutic Effects of Hab Shabyar on Open-Angle Glaucoma: A Double-Blinded, Randomized, Placebo-Controlled Trial

Ebrahim Khalil BaniHabib, Ali Mostafai, Seyyed Mohammad Bagher Fazljou, Ghadir Mohammdi

Background: Open-angle glaucoma (OAG) is one of the leading causes of blindness worldwide. This study evaluates the therapeutic effects of hab shabyar in patients with open-angle glaucoma. Materials and Methods: In this clinical randomized controlled trial, 50 patients with OAG were randomized into two groups. The intervention group was received a drop of timolol plus 500 mg of hab shabyar every 12 hours. The placebo group was received a drop of timolol every 12 hours plus 500 mg of wheat germ as a placebo. The intraocular pressure in patients with OAG was measured in each group and compared at before the intervention (t1), one month (t2), and two months (t3) after the intervention. Results: The mean decrease in intraocular pressure for the right eye at three times in the intervention group was statistically significant, but the mean decrease in the placebo group was not significant. Similar results were obtained for the left eye at t1 when compared to t3. The patients in the intervention group expressed more satisfaction than the patients in the placebo group (P≤0.001). Conclusion: Our study demonstrated that consumption of timolol plus hab shabyar instead of consuming of timolol alone was probably more effective for reducing intraocular pressure in patients with OAG.[GMJ.2019;In press:e1218]

Glaucoma; Open Angle; Hab Shabyar; Timolol

Choplin NT, Traverso CE. Introduction to Glaucoma. Atlas of Glaucoma. 2014:1.

https://doi.org/10.1201/b16796-2

Yaari P. epidemiology textbook of prealent Disease in Iran. First Edition ed. Tehran: Gap publisher; 2014.

Weinreb RN, Khaw PT. Primary open-angle glaucoma. The Lancet. 2004;363(9422):1711-20.

https://doi.org/10.1016/S0140-6736(04)16257-0

Soori H, Ali JM, Nasrin R. Prevalence and causes of low vision and blindness in Tehran Province, Iran. J Pak Med Assoc. 2011;61(6):544. PMid:22204207

Amini H, Javadi M-A, Yazdani S, Pakravan M, Karimian F, Rezaei A, et al. The prevalence of glaucoma in Tehran, Iran. J Ophthalmic Vis Res. 2007;2(2):93-100.

Feghhi M, Khataminia G, Ziaei H, Latifi M. Prevalence and causes of blindness and low vision in Khuzestan province, Iran. J Ophthalmic Vis Res. 2009;4(1):29.

PMid:23056671 PMCid:PMC3448382

Pakravan M, Yazdani S, Javadi M-A, Amini H, Behroozi Z, Ziaei H, et al. A population-based survey of the prevalence and types of glaucoma in central Iran: the Yazd eye study. Ophthalmology. 2013;120(10):1977-84.

https://doi.org/10.1016/j.ophtha.2013.02.029

PMid:23664464

Weih LM, Nanjan M, McCarty CA, Taylor HR. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology. 2001;108(11):1966-72.

https://doi.org/10.1016/S0161-6420(01)00799-0

Varma R, Ying-Lai M, Francis BA, Nguyen BB-T, Deneen J, Wilson MR, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111(8):1439-48.

https://doi.org/10.1016/j.ophtha.2004.01.025

PMid:15288969

Worley A, Grimmer-Somers K. Risk factors for glaucoma: what do they really mean? Australian journal of primary health. 2011;17(3):233-9.

https://doi.org/10.1071/PY10042. PMid:21896259

Coleman AL, Kodjebacheva G. Risk factors for glaucoma needing more attention. Open ophthalmol J. 2009;3:38-42.

https://doi.org/10.2174/1874364100903010038

PMCid:PMC2759104

Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081-90.

https://doi.org/10.1016/j.ophtha.2014.05.013

PMid:24974815

P. Riordan-Eva, J.P. Whitcher: Vaughan and Asbury's General Ophthalmology, 16th edn (Lange Medical Books/McGraw-Hill, New York 2004).

PMCid:PMC1765676

Sina I. Ghanoon Dar Teb [The Canon of Medicine], Bulaq Edition. Sharafkandi A, trans Tehran: Univ of Tehran Pr. 1978.

kermanI A-e. sharh al-asbab wa-al-alamat. Tehran: 2014.

Azam Khan M, Aksir A. The institute of medical history-Islamic and complementary medicine. Tehran, Iran: Iran University of Medical Sciences. 2004.

Organization WH. WHO monographs on selected medicinal plants. World Health Organization; 1999.

Mock C. Guidelines for essential trauma care. World Health Organization; 2004.

Ahmadzadeh J, Rezaeian S, Mobaraki K. The quality of the reporting of randomized controlled trials after CONSORT statement in the prestigious journals. Shiraz E Medical Journal. 2013;14(2):130-8.

Moskowitz JT, Carrico AW, Duncan LG, Cohn MA, Cheung EO, Batchelder A et al. Randomized controlled trial of a positive affect intervention for people newly diagnosed with HIV. Journal of consulting and clinical psychology. 2017;85(5):409.

https://doi.org/10.1037/ccp0000188

PMid:28333512 PMCid:PMC5398944

Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. British journal of ophthalmology. 2006;90(3):262-7.

https://doi.org/10.1136/bjo.2005.081224

PMid:16488940 PMCid:PMC1856963

Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). American journal of ophthalmology. 2018;186:116-27.

https://doi.org/10.1016/j.ajo.2017.11.019

PMid:29199013

Whitcup S, Cantor L, VanDenburgh A, Chen K. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. British journal of ophthalmology. 2003;87(1):57-62.

https://doi.org/10.1136/bjo.87.1.57. PMid:12488264

Ozer MA, Acar M, Yildirim C. Intraocular pressure-lowering effects of commonly used fixed combination drugs with timolol in the management of primary open angle glaucoma. International journal of ophthalmology. 2014;7(5):832. PMid:25349802 PMCid:PMC4206890

Gupta VK, Malhotra S. Pharmacological attribute of Aloe vera: Revalidation through experimental and clinical studies. Ayu. 2012;33(2):193.

https://doi.org/10.4103/0974-8520.105237

PMid:23559789 PMCid:PMC3611630

Soni Y, Mochi R, Gahlot G. EFFECT OFALOE VERA JUICE ON DIABETIC AND DIABETIC RETINOPATHY SUBJECTS. Indian Journal of Life Sciences. 2014;4(1):41.

Serduyk VN. Search form. Oftalmol Zh. 2010;2:67-72.

Saberi M, Gholami S. An investigation on the effects of the Aloe Vera extract on the thickness of the retina in male diabetic rats. Iranian Journal of Veterinary Research. 2012;13(4):296-302.

Refbacks

  • There are currently no refbacks.